Furthermore, another study conducted on diabetic rats with myocardial infarction-associated AKI revealed that pretreatment with empagliflozin for 2 weeks resulted in improved hyperglycemia, elevated blood β-hydroxybutyrate levels, suppressed expression of NGAL and KIM-1 induced by MI, and ultimately prevented the pathogenesis of AKI (Kuno et al., 2020). This evidence concerns the gene LCN2 and acute kidney injury.